CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FierceBiotech
Original article

{"a":[{"_":"AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates","$":{"href":"/biotech/astrazeneca-execs-very-confident-homegrown-adcs-despite-scrapping-2-candidates","hreflang":"en"}}]}

negativeADC pipeline candidatesNeutral
AI Analysis

Summary

AstraZeneca discontinued two antibody-drug conjugate candidates from its in-house pipeline due to clinical underperformance, though executives remain confident in the remaining ADC portfolio.

Outcome Details

Two ADC candidates scrapped due to underperformance in clinical trials

Importance:4/10
Sentiment:
0.10
ADCpipelineclinical_failuredrug_development
Related Companies

Read the original article

Published by FierceBiotech on July 27, 2026 5:35 AM

Read Original